No abstract available.
Blood Glucose* ; Glucose*

No abstract available.
Blood Glucose* ; Glucose*

Type 2 Diabetes Mellitus (T2DM) case management focuses on maintaining therapeutic goals and improving quality of life. Recent evidence highlights the benefits of high-intensity interval training (HIIT) as a therapeutic treatment in T2DM. However, the relationship remains unclear between the effectiveness of HIIT and T2DM. This study aimed to identify published literature that explored the effectiveness of HIIT on T2DM. We conducted a systematic review of existing literature from electronic databases: Pubmed, Proquest, and Science Direct between 2015-2020 according to PRISMA guidelines. Data were extracted based on the PICOS framework. The methodological quality of these studies was assessed using the Critical Appraisal Skills Programme (CASP) tool. Study bias was assessed using Review Manager 5.3. A total of 11 articles from 503 studies were included. Eleven randomized controlled trials found that HIIT programmes obtain a clinically relevant outcome in reducing blood glucose, improving glycemic control with a reduction in HbA1c, reducing capillary glycemia, and decreasing cardiac function. This review suggests that HIIT is effective and safe for managing T2DM. The evidence consistently demonstrates that HIIT improves health condition and reduce risk factors associated with T2DM. It is critical to encourage further research to establish medium to long-term effects and cost-effectiveness of HIIT among individuals with T2DM.
Blood Glucose

BACKGROUND: In diabetic patients, both glucose and hemoglobin A1c (HbA1c) concentrations are frequently measured to monitor glycemic control. We examined the analytical performance of the recently developed, automated, ADAMS bridge system (Arkray, Inc., Japan) consisting of the ADAMS glucose GA-1171 and the ADAMS HbA1c HA-8180 analyzers, which allows the consecutive measurement of glucose and HbA1c concentrations. METHODS: We evaluated precision, linearity, carry-over, effects of hematocrit, and turnaround time. Method comparison was conducted between GA-1171 and UniCel DxC 800 (Beckman Coulter, Inc., USA) and Synchron CX3 Delta (Beckman Coulter) for glucose, and between HA-8180 and HLC-723 G8 (Tosoh Bioscience, Inc., Japan) for HbA1c measurements. RESULTS: Total precision (% CV) in measuring high and low level controls was 1.11% and 1.21% for glucose using GA-1171, and 0.86% and 1.3% for HbA1c using HA-8180, respectively. In the linearity test, R2 was 0.9997, 0.9991 and 0.9973 when measuring plasma glucose (58-532 mg/dL), whole blood glucose (74-401 mg/dL), and HbA1c concentrations (4.7-14.7%), respectively. Good correlation was observed between GA-1171 and DxC 800 (r=0.9987), and between HA-8180 and HLC-723 G8 (r=0.9980). Carry-over effect was less than 0.5% for glucose and HbA1c. Turnaround time was reduced from 7 min (CX3 Delta) and 1.43 min (HLC-723 G8) to 2.16 min (GA-1171) and 1.54 min (HA-8180), respectively, when whole blood glucose and HbA1c concentrations were measured consecutively by the ADAMS bridge system. CONCLUSIONS: The ADAMS bridge system had a simple operating procedure and showed an adequate performance and a rapid turnaround time.
Blood Glucose ; Glucose* ; Hematocrit ; Humans

Study on 50 patients (male: 12, female: 38), between the ages of 72 and 40, with hypertension (62% of patients), obesity (60%) in which abdominal obesity (78%) was carried out in Bach Mai Hospital during July 2000- March 2001. The results found that the lipemia disorder frequently occurred in patients with reduced glucose toleration according to the classification of Fredrichson (type IV). 69% patients with the reduced glucose toleration had a lipemia disorder accompanying with hypertension. The risk of hypertension among these patients was higher 6.7 times than this among patients without the lipemia disorder. 93% patients with the reduced glucose toleration and obesity had a lipemia disorder. This rate in the patients with abnormal obesity was 97%; 100% of patients with the reduced glucose toleration had signs of coronary insufficiency
Glucose ; Lipoprotein Lipase ; Blood Glucose

No abstract available.
Blood Glucose* ; Near Drowning*

No abstract available.
Blood Glucose* ; Plasma*

No abstract available.
Blood Glucose* ; Seizures, Febrile*

No abstract available.
Blood Glucose* ; Seizures, Febrile*

No abstract available.
Blood Glucose* ; Hemoglobin A, Glycosylated*